Researchers in Dr. Karl Deisseroth's lab have created inhibitory channelrhodopsins (ChRs) that allow fast, reversible inhibition of electrical signals in neurons. Optogenetics is a technique used to understand normal and pathological neural circuitry.
Stanford researchers have identified small molecules that can intercept cancerous or pre-cancerous cells by activating DNA repair in cells damaged by oxidative stress.
Researchers in Prof. Paul Khavari's laboratory have discovered a novel compound and method to block invasive neoplasia without effects on normal cells.
Hydrogel-based tissue engineering scaffolds are widely used for culturing cells in three dimensions (3D) due to their tissue-like water content, tunable biochemical and physical properties, and ease of cell encapsulation and distribution in 3D.
Researchers in Dr. Shatz's lab have identified murine PirB and its human ortholog LilrB2 as receptors for β-amyloid (Aβ) oligomers. Aβ oligomers play a central role in a number of pathologies.
Researchers in Prof. Karl Deisseroth's laboratory have developed specific, inducible animal models for depression that use targeted optogenetic strategies to precisely dissect the neuronal circuits underlying the condition.
Researchers in Prof. Karl Deisseroth's laboratory have developed a system to enhance optogenetic pumps using one tool to address current limitations in both inhibition and excitation.
Researchers in Prof. Robert Malenka's laboratory have developed a light-activated animal system that could be used to identify compounds that treat certain psychiatric disorders.
The transplantation of retinal pigment epithelial cells (RPEs) or iris pigment epithelial cells (IPEs) to rescue diseased photoreceptors in the subretinal space is one of the leading experimental therapies for Age-Related Macular Degeneration, the most common form of blindness
Researchers in Dr. Fan Yang's lab have developed 3D tissue engineering scaffolds with dynamic, temporally and spatially controllable macropore formation.
Researchers in Dr. Bingwei Lu's lab have identified genes that could serve as therapeutic targets for the treatment of Parkinson's disease (PD). PD is a common neurodegenerative movement disorder affecting 1% of the population over the age 60.
Stanford and Rockefeller researchers have identified and developed dynein-specific inhibitors that have significant medical applications involving mitotic spindle assembly, organelle transport, and primary cilia formation.
Researchers in Dr. Michael Cleary's laboratory at Stanford University have developed a highly specific monoclonal antibody for AF5, a proto-oncoprotein associated with pediatric and adult acute leukemia.
A method of using neuregulin antagonists to delay the time of tumor recurrence in cancer patients has been developed by Dr. Sweet-Cordero and collaborators. This technology is available for non-exclusive license.